Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck begins desmoteplase phase III trial

Lundbeck begins desmoteplase phase III trial

17th December 2008

Lundbeck has commenced a clinical phase III programme investigating the use of desmoteplace to treat ischemic stroke.

According to the company, about four in every five stroke patients are not ready for treatment until at least three hours after the event, due to non-diagnosis.

However, current medical options approved for stroke victims are only to be applied up to three hours after the attack.

Lundbeck has therefore consulted with authorities to design the phase III trials with the aim of administering desmoteplase (one dose of 90 mg/kg) within a three to nine hour window.

“Desmoteplase has the potential to treat patients with acute ischaemic stroke up to nine hours after onset of symptoms,” said executive vice-president and head of development at the company Anders Gersel Pedersen.

“That is up to six hours more than existing treatment.”

He added that the product could potentially become of “significant benefit” to stroke patients.

The two phase III trials are set to enrol people from the USA, Europe, Canada, Asia and South America and last 90 days.

Earlier this week, Lundbeck said it was continuing with the development of nalmefene as a treatment for alcohol dependence.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.